IRBMWe are Italy’s largest independent Partner Research Organization for drug discovery and preclinical development. Established in 1999 as the Italian site of Merck Research Laboratories, we were divested by Merck in 2009, and reopened in 2010 as an independent company, retaining the scientific team responsible for the development of five marketed drugs as of 2017.

Our core expertise extends from assay development and high-throughput screening to in vivo preclinical pharmacology assessments. Our team consists of over 180 experienced chemists and biologists with extensive industry experience, providing not just the ability to pursue your project, but also the scientific advice and expertise it needs to advance quickly and efficiently from a validated target to a strong drug candidate.

With over 25 preclinical candidates delivered in nine years, more than 100 patents, more than 800 publications, and a pedigree of excellence in small molecules and peptide chemistry, we champion your discovery and development pipeline through proven, world-class expertise and a strong record of success.